St. Jude found 156 potential targets for chimeric antigen receptor (CAR) T--cell immunotherapy. Explore the discovery's promise to improve cancer therapies. Targeting anti-cancer therapy to affect ...
New company Pan Cancer T BV is preparing for a clinical trial of a next-generation T-cell receptor-engineered T cell it has designed to remove the current barriers and make T-cell therapies effective ...
A pan-cancer analysis of 2,930 patients across 11 tumor types found that ALK mutation was associated with significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results